Latest Diabetes News
Significantly higher mortality in the Diabetes Control and Complications Trial conventional therapy group.
The study highlights a need to monitor eGFR regularly, even in patients who have yet to develop renal impairment of concern.
Significantly lower rates of admission for stroke, heart failure, pneumonia/influenza, all-cause-death.
A post-hoc analysis was conducted on the effect of saxagliptin 2.5 mg and 5 mg vs. placebo on glycemic measures.
HbA1c targets are not linked to patient variables including biological, physical, or mental health.
A meta-analysis has determined that metformin is still the first-line treatment for diabetes.
The Mediterranean Diet may reduce patients risks of breast cancer, cardiovascular disease, and diabetes.
Notably, gliclazide did not appear superior to other sulfonylureas.
Patients with depression were younger, had higher eGFR, and more comorbidities.
Reduction in HbA1c with both lixisenatide, glulisine; less hypoglycemia with lixisenatide
Lower mean HbA1c, more diabetes remission, more weight loss versus lifestyle-medical management.
Diabetics taking the drug had a significant 68% decreased risk of grade progression compared with diabetics not on the drug.
Greater reduction in hemoglobin A1c, greater reduction in fasting plasma glucose with liraglutide.
Study points to need for better coordinated care, more effective use of medications.
Those with type 2 diabetes and heart disease as well as a prior cardiovascular event have an increased risk of cardiovascular mortality.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)